SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

HC Wainwright & Co. reiterated a Buy rating on SpyGlass Pharma with a $37 price target, suggesting a 41.4% upside from the Oct 20 close. The analyst highlights promising clinical data showing a 37% reduction in intraocular pressure and 86% of patients off IOP-lowering drops, supporting the company's drug-delivery platform.

SpyGlass Pharma (SGP) reported 4-year trial data for its BIM-IOL System, showing a 37% mean reduction in intraocular pressure (IOP) and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to pursue a 505(b)(2) NDA with the FDA, with Phase 3 trials ongoing. The BIM-IOL System is designed to deliver bimatoprost for up to 7 years from a single implant during cataract surgery.

SpyGlass Pharma reported 4-year data for its BIM-IOL System, showing a 37% mean reduction in intraocular pressure and 86% of patients off topical drops. The trial had no product-related adverse events, and 90% of patients maintained good visual acuity. The company continues long-term follow-up and Phase 3 enrollment.

SpyGlass Pharma (SGP) reported four-year data from a study of its BIM-IOL System, showing a 37% reduction in mean intraocular pressure in patients with glaucoma or ocular hypertension. 86% of patients remained off eye drops, with no product-related adverse events. The system is in Phase 3 trials, aiming for a potential FDA submission.

SpyGlass Pharma (NASDAQ: SGP) reported 4-year trial results for its Bimatoprost Drug Pad-IOL System, showing a 37% reduction in intraocular pressure and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to advance the program through FDA submission.